Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis-developed drug to be trialled

Novartis-developed drug to be trialled

31st March 2008

A new trial has been started to determine the effectiveness of rufinamide as a treatment for anxiety, it has emerged.

The announcement was made by Synosia Therapeutics and stated that the sodium channel blocker could be an effective treatment for general anxiety disorder, based on the “encouraging results” of a proof-of-concept study which were released earlier this year.

Rufinamide, which was developed by Novartis, is currently used in Europe to treat a type of epilepsy, although it is also thought to be a potential treatment for mood disorders, including anxiety.

“Given the extensive safety experience available from previous studies, we believe this structurally novel compound has the potential to relieve anxiety without the adverse side effects of current treatments,” stated Synosia’s chief medical officer Stephen Bandak.

Mr Bandak added that there is a “real need” for new treatment options for anxiety disorders and that rufinamide has a lower risk of dependence than other benxoidazepine-based treatments.

Under partnerships with Roche, Novartis and Syngenta, Synosia Therapeutics is currently testing two marketed drugs for their effectiveness at treating Parkinson’s disease and anxiety.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.